Genovate Biotechnology Co (ROCO:4130) Beneish M-Score: -2.61 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
72 GF Score
Price NT$26.85
GF Value NT$22.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co Beneish M-Score?

Genovate Biotechnology Co ROCO:4130 -4.62% 72 Beneish M-Score is -2.61 as of Jul. 14, 2026. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 825 Biotechnology companies, Genovate Biotechnology Co ranks better than 60.73% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Genovate Biotechnology Co's Beneish M-Score or its related term are showing as below:

ROCO:4130' s Beneish M-Score Range Over the Past 10 Years
Min: -2.78   Med: -2.59   Max: -1.97
Current: -2.61

During the past 13 years, the highest Beneish M-Score of Genovate Biotechnology Co was -1.97. The lowest was -2.78. And the median was -2.59.


Genovate Biotechnology Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Beneish M-Score Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.97 -2.42 -2.78 -2.59 -2.61

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 -2.92 -2.55 -2.65 -2.61

ROCO:4130 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Genovate Biotechnology Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovate Biotechnology Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genovate Biotechnology Co's Beneish M-Score falls into.


ROCO:4130
72GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genovate Biotechnology Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0043+0.528 * 1.049+0.404 * 0.9229+0.892 * 0.9639+0.115 * 1.0158
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0608+4.679 * -0.021314-0.327 * 0.9619
=-2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$87.6 Mil.
Revenue was 119.401 + 115.527 + 126.172 + 131.306 = NT$492.4 Mil.
Gross Profit was 40.594 + 40.81 + 48.315 + 47.303 = NT$177.0 Mil.
Total Current Assets was NT$719.3 Mil.
Total Assets was NT$1,506.4 Mil.
Property, Plant and Equipment(Net PPE) was NT$410.4 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$38.7 Mil.
Selling, General, & Admin. Expense(SGA) was NT$112.2 Mil.
Total Current Liabilities was NT$125.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.6 Mil.
Net Income was -3.732 + -1.471 + 7.34 + 9.545 = NT$11.7 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was 16.93 + 12.136 + -26.501 + 41.224 = NT$43.8 Mil.
Total Receivables was NT$90.5 Mil.
Revenue was 118.221 + 126.376 + 126.9 + 139.359 = NT$510.9 Mil.
Gross Profit was 39.078 + 47.246 + 50.228 + 56.097 = NT$192.6 Mil.
Total Current Assets was NT$765.5 Mil.
Total Assets was NT$1,590.2 Mil.
Property, Plant and Equipment(Net PPE) was NT$394.0 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$37.8 Mil.
Selling, General, & Admin. Expense(SGA) was NT$109.7 Mil.
Total Current Liabilities was NT$136.5 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(87.567 / 492.406) / (90.458 / 510.856)
=0.177835 / 0.177071
=1.0043

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(192.649 / 510.856) / (177.022 / 492.406)
=0.37711 / 0.359504
=1.049

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (719.298 + 410.424) / 1506.369) / (1 - (765.452 + 393.951) / 1590.214)
=0.250036 / 0.270914
=0.9229

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=492.406 / 510.856
=0.9639

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(37.835 / (37.835 + 393.951)) / (38.745 / (38.745 + 410.424))
=0.087624 / 0.086259
=1.0158

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(112.202 / 492.406) / (109.735 / 510.856)
=0.227865 / 0.214806
=1.0608

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.607 + 125.322) / 1506.369) / ((1.728 + 136.48) / 1590.214)
=0.083598 / 0.086912
=0.9619

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(11.682 - 0 - 43.789) / 1506.369
=-0.021314

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genovate Biotechnology Co has a M-score of -2.61 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.61 mean?
Genovate Biotechnology Co (ROCO:4130) has a Beneish M-Score of -2.61 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genovate Biotechnology Co and its competitors. According to the industry distribution chart, Genovate Biotechnology Co ranks #324 out of 825 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Genovate Biotechnology Co's Beneish M-Score too high?
Genovate Biotechnology Co's current Beneish M-Score is -2.61. Based on the distribution chart, Genovate Biotechnology Co ranks #324 out of 825 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #324 out of 825 companies for Beneish M-Score. This puts Genovate Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current Beneish M-Score is -2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Beneish M-Score is -2.61. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Beneish M-Score is -2.61 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • Beneish M-Score: -2.61
  • GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score

Get the complete analysis for ROCO:4130

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.85
Price
NT$22.20
GF Value